The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
but I would say although this study will never be done if you're a newly diagnosed diabetic and you don't have any cardiac symptoms why do you think that the sglt2 inhibitor is not doing all of the beneficial things in that newly diagnosed diabetic that it's doing and the people who get into these studies who already have cardiac disease
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and uh for sure uh if you had any kind of renal cardiac disease I'm going to pick an estl T2 inhibitor
if you have a cardiac problem I put you on the sglt2 inhibitor you're less likely to have Mi stroke Etc it's doing good things it's doing in my opinion the exact same good thing in someone who I'm just diagnosing for the first time when I put them on the hlt2 inhibitor but no one is ever going to do a study it's impossible